SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis

Sagnelli, Caterina; Macera, Margherita; Camaioni, Clarissa; Salvati, Annabella; Coppola, Nicola; Sagnelli, E.

doi:10.1007/s15010-022-01804-z

Cited by 9 publications

(9 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, the total number of treated patients decreased. Other researchers point to the negative impact of the coronavirus disease 2019 (COVID-19) pandemic on the number of diagnosed and treated patients with chronic HCV infection[ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Brzdęk¹,

Zarębska-Michaluk²,

Rzymski³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND Nearly 290000 patients with chronic hepatitis C die annually from the most severe complications of the disease. One of them is liver cirrhosis, which occurs in about 20% of patients chronically infected with the hepatitis C virus (HCV). Direct-acting antivirals (DAAs), which replaced interferon (IFN)-based regimens, significantly improved the prognosis of this group of patients, increasing HCV eradication rates and tolerability of therapy. Our study is the first to assess changes in patient profile, effectiveness, and safety in the HCV-infected cirrhotic population in the IFN-free era. AIM To document changes in patient characteristics and treatment regimens along with their effectiveness and safety profile over the years. METHODS The studied patients were selected from 14801 chronically HCV-infected individuals who started IFN-free therapy between July 2015 and December 2021 in 22 Polish hepatology centers. The retrospective analysis was conducted in real-world clinical practice based on the EpiTer-2 multicenter database. The measure of treatment effectiveness was the percentage of sustained virologic response (SVR) calculated after excluding patients lost to follow-up. Safety data collected during therapy and the 12-wk post-treatment period included information on adverse events, including serious ones, deaths, and treatment course. RESULTS The studied population ( n = 3577) was balanced in terms of gender in 2015-2017, while the following years showed the dominance of men. The decline in the median age from 60 in 2015-2016 to 57 years in 2021 was accompanied by a decrease in the percentage of patients with comorbidities and comedications. Treatment-experienced patients dominated in 2015-2016, while treatment-naive individuals gained an advantage in 2017 and reached 93.2% in 2021. Genotype (GT)-specific options were more prevalent in treatment in 2015-2018 and were supplanted by pangenotypic combinations in subsequent years. The effectiveness of the therapy was comparable regardless of the period analyzed, and patients achieved an overall response rate of 95%, with an SVR range of 72.9%-100% for the different therapeutic regimens. Male gender, GT3 infection, and prior treatment failure were identified as independent negative predictors of therapeutic success. CONCLUSION We have documented changes in the profile of HCV-infected cirrhotic patients over the years of accessibility to changing DAA regimens, confirming the high effectiveness of IFN-free therapy in all analyzed periods.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Brzdęk¹,

Zarębska-Michaluk²,

Rzymski³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Oncological patients suffered many consequences of the COVID-19 pandemic. In the initial phases of the pandemic, the accessibility to diagnostic and therapeutic pathways was impaired due to the conversion of several departments into COVID-19 units, causing disruptions to oncological screening, treatment, and surveillance [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ]. Additionally, COVID-19 infection can cause serious complications in oncological patients undergoing chemotherapy or recovering from recent surgery [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: The COVID-19 outbreak had a massive impact on lung cancer patients with the rise in the incidence and mortality of lung cancer. Methods: We evaluated whether a recent COVID-19 infection affected the outcome of patients undergoing thoracoscopic lobectomy for lung cancer using a retrospective observational mono-centric study conducted between January 2020 and August 2022. Postoperative complications and 90-day mortality were reported. We compared lung cancer patients with a recent history of COVID-19 infection prior to thoracoscopic lobectomy to those without recent COVID-19 infection. Univariable and multivariable analyses were performed. Results: One hundred and fifty-three consecutive lung cancer patients were enrolled. Of these 30 (19%), had a history of recent COVID-19 infection prior to surgery. COVID-19 was not associated with a higher complication rate or 90-day mortality. Patients with recent COVID-19 infection had more frequent pleural adhesions (p = 0.006). There were no differences between groups regarding postoperative complications, conversion, drain removal time, total drainage output, and length of hospital stay. Conclusions: COVID-19 infection did not affect the outcomes of thoracoscopic lobectomy for lung cancer. The treatment of these patients should not be delayed in case of recent COVID-19 infection and should not differ from that of the general population.

show abstract

“…The decreased population immunity resulting from reduced exposure to respiratory pathogens during the SARS-CoV-2 pandemic may render individuals more susceptible to these infections. Additionally, the strain on healthcare systems and resources caused by the management of SARS-CoV-2 may impede the timely diagnosis and treatment of other chronic or infectious diseases [28,37,38]. Therefore, it is crucial to establish comprehensive surveillance systems, implement targeted vaccination campaigns, and raise public health awareness to address the challenges posed by the resurgence of respiratory pathogen infections.…”

Section: Discussionmentioning

confidence: 99%

Changes in Spectrum of Respiratory Pathogen Infections and Disease Severity Among Children in Hohhot: Impact of COVID-19 Prevention Measures

Gan

Yang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Acute respiratory infections (ARIs) are caused by various pathogens, and the outbreak of the novel coronavirus has led to changes in the patterns of respiratory pathogen infections. Through long-term study of respiratory tract infection data in children from Hohhot, significant differences in the spectrum of respiratory pathogen infections, disease severity, and seasonal patterns have been discovered between 2022 and 2023. Methods Throat swabs were collected from 605 children with ARIs at the First Hospital of Hohhot, and pathogen detection was performed using microarray technology. Blood biomarkers, symptoms, and clinical diagnoses were evaluated. Results The study found that 56.03% of the patients were male, with an average age of 3.45 years. Pathogen dynamics revealed that SARS-CoV-2 was the most prevalent infection, accounting for 262 cases. It persisted from October 2022 to January 2023 and then disappeared. Influenza A virus (IAV) cases peaked in March 2023. Respiratory syncytial virus (RSV), Influenza B virus (IBV), Parainfluenza virus (PIV), Mycoplasma pneumoniae (M. pneumoniae), Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Group A streptococcus (GAS) were not detected after December 2022. The proportion of mixed infections was 41.94% among SARS-CoV-2 patients, while other pathogens had mixed infection rates exceeding 57.14%. Before December 2022, the mean value of white blood cell (WBC) count for Streptococcus pneumoniae (S. pneumoniae), Haemophilus influenzae (H. influenzae), Epstein-Barr virus (EBV), and Cytomegalovirus (CMV) was 8.83*10^9/L, C-reactive protein (CRP) was 18.36 mg/L, and procalcitonin (PCT) was 1.11 ng /ml. After December 2022, these values decreased to 5.5*10^9/L, 6.33 mg/L, and 0.24 ng /ml, respectively. Similarly, the proportion of patients with cough, difficulty breathing, and running nose, as well as the diagnosis of lower respiratory tract infections, decreased in December 2022. However, the situation was different for SARS-CoV-2 infections. Conclusions Strict SARS-CoV-2 policies reduced the infection risk for S. pneumoniae, H. influenzae, EBV, and other pathogens before November 2022. However, patient symptoms worsened compared to after November 2022, possibly due to an excessive focus on SARS-CoV-2, neglecting other diseases, and reduced population immunity to respiratory infections.

show abstract

SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis

Cited by 9 publications

References 53 publications

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

Changes in Spectrum of Respiratory Pathogen Infections and Disease Severity Among Children in Hohhot: Impact of COVID-19 Prevention Measures

Contact Info

Product

Resources

About